PharmAlert.net

PharmAlert Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Farmaexplorer.it

Diabetes mellitus: the REMS is no longer necessary to ensure that the benefits of Rosiglitazone medicines outweigh their risks


The FDA ( Food and Drug Administration ) is eliminating the Risk Evaluation and Mitigation Strategy ( REMS ) for Rosiglitazone-containing type 2 diabetes medicines, which are approved as Avandia, Avandamet, Avandaryl, and generics.
The REMS is no longer necessary to ensure that the benefits of Rosiglitazone medicines outweigh their risks.

In 2013, FDA required removal of the prescribing and dispensing restrictions for Rosiglitazone medicines after determining that data did not demonstrate an increased risk of myocardial infarction with Rosiglitazone medicines compared to the standard type 2 diabetes medicines Metformin and sulfonylurea.
FDA also required the drug manufacturers to provide educational training to health care professionals about the current state of knowledge regarding the heart risks of Rosiglitazone medicines.
Manufacturers have since fulfilled these requirements.

FDA has continued monitoring these medicines and identified no new pertinent safety information.

Type 2 diabetes is a disease that can lead to serious complications such as kidney failure, blindness, and premature death.
Rosiglitazone can be used along with diet and exercise to control blood sugar in adults with the disease. ( Xagena )

Source: FDA, 2015

XagenaMedicine_2015



Indietro